ALLO

Conviction 60HealthcareScan · Tue, Sep 8, 2026

ALLO$1.85-6.09%

ResistanceSupportVol 14Insider sell

Vol MA14 5.54M

Jun 9Jun 26Jul 16Aug 3Aug 20Sep 8

Allogene Therapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.allogene.com ↗

Price1.85

Change-6.09%

Gap-2.03%

Rel volume2.91×

Avg volume5.34M

Avg $ vol10.85M

SMA 202.04

SMA 501.98

SMA 2001.97

Price vs 50-6.52%

Price vs 200-6.06%

MA stackmixed

50/200 cross—

Supertrendup · 1.78

RSI (14)40

MACD hist-0.02

MACD crossbear · 6d

Stoch %K / %D0 / 14

ADX (14)13

+DI / −DI17 / 21

RSI divergence—

MACD divergence—

ATR %+6.18%

ADR %5.56%

52w high3.06

52w low1.05

From 52w high-39.54%

Above 52w low+76.19%

New 52w highNo

SqueezeFired

Bollinger width15.63%

%B-0.11

Donchian pos0.00%

Donchian high2.23

Donchian low1.85

AVWAP (52w high)2.22

vs AVWAP high-16.83%

AVWAP (52w low)2.12

vs AVWAP low-12.87%

OBV trendDown

Chaikin MF (20)-0.14

Today vs 20d2.91×

Avg vol (14d)5.54M

Avg vol (20d)5.34M

Avg $ vol (20d)10.85M

Market cap639.16M

RS 3m (vs SPY)+0.36%

RS 6m (vs SPY)-28.89%

RS line new highNo

Trend template4/8

Technical rank14.9

1 week-7.50%

1 month-7.96%

3 months+0.00%

6 months-26.00%

1 year+60.87%

YTD+37.04%

P/E-3.35

P/B1.47

P/S—

P/FCF-4.27

EPS-0.8700

Div yield—

ROE-43.76%

ROA-34.70%

Debt/Eq—

Current10.72

EV/EBITDA-3.05

Gross margin—

Net margin—

Rev growth-100.00%

EPS growth25.90%

Price target10.25

Target upside454.05%

Analyst ratingBuy

Institutional88.34%

Ent. value600.53M

Revenue4.64M

Net income-42.68M

Gross profit—

Free cash flow-149.63M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out345.15M

Employees152

ListedThu, Oct 11, 2018

Free float169.95M

Float %69.4%

Short interest58.95M

Days to cover11.9d

Short volume69.3%

Squeeze score100 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.13 vs −$0.16

Last surprise+18.8% beat

Setup gradeB

Conviction60 / 100

Pattern quality—

Tech rank14.9 / 100

Group rank96 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance2.22

Support1.68

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ALLO

All disclosures →

No recent disclosed trades by Congress in ALLO. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ALLO · 2 buys · 2 sells

Insider	Side	Shares	Value	Traded	Filed
Douglas Earl Martin SVP, General Counsel · Common Stock · 2026-08-21	Sell	29.7K	$63K	2026-08-21	2026-08-25
Roberts Zachary President and CEO · Restricted Stock Unit · 2026-07-01	Grant	134.53K	—	2026-07-01	2026-07-06
Roberts Zachary President and CEO · Stock Option (Right to buy) · 2026-07-01	Grant	476.19K	—	2026-07-01	2026-07-06
Yoshiyama Annie SVP, Finance · Common Stock · 2026-04-21	Sell	9.59K	$22K	2026-04-21	2026-04-23

SEC filings

EDGAR filings in ALLO · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.